SIGA Produces FDA Registration Batches of ST-246(r) Drug Product Read more about SIGA Produces FDA Registration Batches of ST-246(r) Drug Product SIGA to Respond to Barda's Request for Proposal Seeking 1.7 Million Courses of Smallpox Antiviral Read more about SIGA to Respond to Barda's Request for Proposal Seeking 1.7 Million Courses of Smallpox Antiviral ST-246(r) in Combination With the Smallpox Vaccine ACAM2000(tm) Confers Protective Immunity in Primates Read more about ST-246(r) in Combination With the Smallpox Vaccine ACAM2000(tm) Confers Protective Immunity in Primates BARDA Issues a Presolicitation for Acquisition of a Smallpox Antiviral Read more about BARDA Issues a Presolicitation for Acquisition of a Smallpox Antiviral SIGA Clarifies European Regulatory Path for Lead Smallpox Anti-viral ST-246 Read more about SIGA Clarifies European Regulatory Path for Lead Smallpox Anti-viral ST-246 SIGA Completes Manufacture of ST-246 Registration Batches Read more about SIGA Completes Manufacture of ST-246 Registration Batches SIGA Technologies Completes Human Pharmacokinetic Bridging Study Validating Commercial Formulation Read more about SIGA Technologies Completes Human Pharmacokinetic Bridging Study Validating Commercial Formulation SIGA to Present ST-246 to the World Health Organization Read more about SIGA to Present ST-246 to the World Health Organization SIGA Technologies to Present At the Rodman and Renshaw Annual Global Investment Conference Read more about SIGA Technologies to Present At the Rodman and Renshaw Annual Global Investment Conference SIGA Applauds Efforts to Promote Private Sector Participation in Smallpox Biodefense Read more about SIGA Applauds Efforts to Promote Private Sector Participation in Smallpox Biodefense Pagination First page « First Previous page ‹ Previous … Page 19 Page 20 Page 21 Page 22 Current page 23 Page 24 Page 25 Page 26 Page 27 … Next page Next › Last page Last » Subscribe to
SIGA Produces FDA Registration Batches of ST-246(r) Drug Product Read more about SIGA Produces FDA Registration Batches of ST-246(r) Drug Product
SIGA to Respond to Barda's Request for Proposal Seeking 1.7 Million Courses of Smallpox Antiviral Read more about SIGA to Respond to Barda's Request for Proposal Seeking 1.7 Million Courses of Smallpox Antiviral
ST-246(r) in Combination With the Smallpox Vaccine ACAM2000(tm) Confers Protective Immunity in Primates Read more about ST-246(r) in Combination With the Smallpox Vaccine ACAM2000(tm) Confers Protective Immunity in Primates
BARDA Issues a Presolicitation for Acquisition of a Smallpox Antiviral Read more about BARDA Issues a Presolicitation for Acquisition of a Smallpox Antiviral
SIGA Clarifies European Regulatory Path for Lead Smallpox Anti-viral ST-246 Read more about SIGA Clarifies European Regulatory Path for Lead Smallpox Anti-viral ST-246
SIGA Completes Manufacture of ST-246 Registration Batches Read more about SIGA Completes Manufacture of ST-246 Registration Batches
SIGA Technologies Completes Human Pharmacokinetic Bridging Study Validating Commercial Formulation Read more about SIGA Technologies Completes Human Pharmacokinetic Bridging Study Validating Commercial Formulation
SIGA to Present ST-246 to the World Health Organization Read more about SIGA to Present ST-246 to the World Health Organization
SIGA Technologies to Present At the Rodman and Renshaw Annual Global Investment Conference Read more about SIGA Technologies to Present At the Rodman and Renshaw Annual Global Investment Conference
SIGA Applauds Efforts to Promote Private Sector Participation in Smallpox Biodefense Read more about SIGA Applauds Efforts to Promote Private Sector Participation in Smallpox Biodefense